ICU Medical (ICUI) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICU Medical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ICUI shares.
View ICUI analyst ratings or view top-rated stocks.

2 brokers have issued 1 year price targets for ICU Medical's stock. Their ICUI share price forecasts range from $190.00 to $216.00. On average, they predict the company's stock price to reach $203.00 in the next year. This suggests a possible upside of 6.3% from the stock's current price.
View analysts price targets for ICUI or view top-rated stocks among Wall Street analysts.

ICU Medical's stock was trading at $157.48 at the start of the year. Since then, ICUI stock has increased by 21.2% and is now trading at $190.92.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ICUI earnings forecast.

ICU Medical, Inc. (NASDAQ:ICUI) released its quarterly earnings results on Wednesday, November, 3rd. The medical instruments supplier reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.57 by $0.50. The medical instruments supplier had revenue of $336.06 million for the quarter, compared to the consensus estimate of $314.20 million. ICU Medical had a negative net margin of 2.00% and a positive trailing twelve-month return on equity of 6.42%. During the same quarter in the previous year, the business posted $1.61 EPS.

ETFs with the largest weight of ICU Medical (NASDAQ:ICUI) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), First Trust Health Care AlphaDEX Fund (FXH), VanEck Morningstar SMID Moat ETF (SMOT), FIS Knights of Columbus Global Belief ETF (KOCG), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares S&P Mid-Cap 400 Value ETF (IJJ) and SPDR S&P 400 Mid Cap Value ETF (MDYV).

81 employees have rated ICU Medical Chief Executive Officer Vivek Jain on Glassdoor.com. Vivek Jain has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ICU Medical investors own include Becton, Dickinson and (BDX), BlackRock (BLK), NVIDIA (NVDA), Alibaba Group (BABA), CA (CA), UnitedHealth Group (UNH), Boeing (BA), Micron Technology (MU), Lockheed Martin (LMT) and ServiceNow (NOW).

ICU Medical trades on the NASDAQ under the ticker symbol "ICUI."

ICU Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (9.19%), BlackRock Inc. (7.30%), JPMorgan Chase & Co. (3.24%), State Street Corp (2.56%), Victory Capital Management Inc. (2.49%) and Nuance Investments LLC (2.14%). Insiders that own company stock include Daniel Woolson, Elisha W Finney, George A Lopez, Robert S Swinney, Virginia Ruth Sanzone and Vivek Jain.
View institutional ownership trends.

Shares of ICUI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICUI stock can currently be purchased for approximately $190.92.

ICU Medical (NASDAQ:ICUI) has a market capitalization of $4.59 billion and generates $2.28 billion in revenue each year. The medical instruments supplier earns $-74,290,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

The company employs 14,500 workers across the globe.

ICU Medical's mailing address is 951 CALLE AMANECER, SAN CLEMENTE CA, 92763. The official website for the company is www.icumed.com. The medical instruments supplier can be reached via phone at (949) 366-2183, via email at ir@icumed.com, or via fax at 949-366-8368.